Feb

2012

CircuLite, Inc.: Series D $30M

Posted in I - Series D, Q - 4Q11, R - NORTH EAST, X - Device (Cardiology), XX - NJ

CircuLite (Saddle Brook, NJ) a clinical-stage medical device company focused on minimally invasive implantable devices for chronic heart failure, closed a $30M Series D financing. Participants include Forbion Capital Partners and MacAndrews & Forbes Holdings.

Jan

2012

Innopharma, Inc.: Series A $15M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Device (Delivery), X - Generics, X - Injectable, X - Opthalmology, XX - NJ

Innopharma (Piscataway, NJ) a development-stage specialty pharmaceutical company focused on generics and drug delivery technology platforms for existing drugs, closed a $15M Series A financing. Participants include Thomas, McNerney & Partners.

Oct

2011

Valeritas, Inc.: Series C $150M

Posted in I - Series C, Q - 3Q11, R - NORTH EAST, X - Device (Delivery), X - Device (Diabetes), XX - NJ

Valeritas (Bridgewater, NJ) a commercial-stage developer of a disposable insulin delivery device, closed a $150M Series C financing. Participants include Welsh, Carson, Anderson & Stowe, MPM Capital, Pitango Venture Capital, Abingworth Management, Advanced Technology Ventures, Onset Ventures, HLM Venture Partners, Agate Medical Investments, CHL Medical Partners and Kaiser Permanente Ventures.

Apr

2011

PanOptica, Inc.: Series A $30M

Posted in I - Series A, Q - 1Q11, R - NORTH EAST, X - Opthalmology, XX - NJ

PanOptica (Mount Arlington, NJ) a development-stage biopharma company focused on in licensing IND-stage ophthalmology assets, closed a $30M Series A financing. Participants include SV Life Sciences and Third Rock Ventures.

Mar

2011

Omthera Pharmaceuticals, Inc.: Series B $33.9M

Posted in I - Series B, Q - 1Q11, R - NORTH EAST, X - Cardiology, X - FA, XX - NJ

Omthera Pharmaceuticals (Bedminster, NJ) a clinical-stage specialty biopharma company focused on an Omega-3 fatty acid containing DHA and EPA as a therapy for dyslipidemia, closed a $33.9M Series B financing. Participants include New Enterprise Associates and Sofinnova Ventures.

Mar

2011

Aerie Pharmaceuticals, Inc.: Series B $41.3M

Posted in I - Series B, Q - 1Q11, R - NORTH EAST, X - Opthalmology, XX - NJ

Aerie Pharmaceuticals (Bridgewater, NJ) a clinical-stage biotechnology company focused on the treatment of glaucoma and other ophthalmic disease, closed a $41.3M Series B financing. Participants include Alta Partners and Sofinnova Ventures.

Jan

2011

Prolong Pharmaceuticals, Inc.: Series C $30M

Posted in I - Series C, Q - 4Q10, R - NORTH EAST, X - Cardiology, XX - NJ

Prolong Pharmaceuticals (South Plainfield, NJ) a near clinical-stage biopharmaceuticals company focused sickle cell anemia, stroke and diabetic induced ischemia, closed a $30M Series C financing. Participants were not identified.

Dec

2010

Tyrx, Inc.: Series C $16M

Posted in I - Series C, Q - 4Q10, R - NORTH EAST, X - Antibacterial, X - Device (Cardiology), X - Drug:Device Combo, XX - NJ

Tyrx (Monmouth Junction, NJ) a commercial-stage drug:device combo company focused on a dissolving antibacterial biocompatible mesh envelope to house implanted devices such as pacemakers and defibrillators, closed a $16M Series C financing. Participants include HLM Venture Partners, Clarus Ventures and Pappas Ventures.

Oct

2010

Tobria Therapeutics, Inc.: Series B $31M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - Antiviral, X - HIV, X - Inflammation, XX - NJ

Tobira Therapeutics (Manalapan, NJ) a clinical-stage biopharmaceutical company focused on antivirals for HIV and inflammation, closed a $31M B financing. Participants include Novo Ventures, Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.

Sep

2010

Celator Pharmaceuticals, Inc.: Series D $20M

Posted in I - Series D, Q - 3Q10, R - NORTH EAST, X - Oncology, X - Therapeutic Platform, XX - NJ

Celator Pharmaceuticals (Princeton, NI) a clinical-stage small molecule company focused on acute myeloid leukemia and colorectal cancer, closed a $20M Series D financing. Participants have included Thomas McNerney & Partners, BDC Venture Capital, Domain Associates, GrowthWorks Capital, Quaker BioVentures, TL Ventures and Ventures West.

Jul

2010

Agile Therapeutics, Inc.: Series B $45M

Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Contraception, X - Drug:Device Combo, XX - NJ

Agile Therapeutics (Princeton, NJ) a clinical-stage pharmaceutical company focused on hormonal contraception, closed a $45M Series B financing. Participants include Investor Growth Capital, Care Capital, ProQuest Investments, Kaiser Permanente Ventures and Novitas Capital.

Mar

2010

Omthera Pharmaceuticals, Inc.: Series A $6.5M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Cardiology, X - FA, XX - NJ

Omthera Pharmaceuticals (Bedminster, NJ) a clinical-stage specialty biopharma company focused on an Omega-3 fatty acid containing DHA and EPA as a therapy for dyslipidemia, closed a $6.5M Series A financing. Participants include Sofinnova Partners.

Mar

2010

Somnus Therapeutics, Inc.: Series A $15M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Insomnia, XX - NJ

Somnus Therapeutics (Bedminster, NJ) a clinical-stage specialty pharmaceutical company focused on a delayed-release sleep-maintenance therapy, closed a $15M Series A financing. Participants include CTI Life Sciences Fund and Care Capital.

« Previous Entries

to top of page...